Research programme: AAV-cDNA gene therapeutics - Sangamo Therapeutics

Drug Profile

Research programme: AAV-cDNA gene therapeutics - Sangamo Therapeutics

Alternative Names: AAV-cDNA gene therapy - Sangamo Therapeutics; ST 920

Latest Information Update: 31 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sangamo Therapeutics
  • Class Gene therapies
  • Mechanism of Action Alpha-galactosidase stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Fabry's disease

Most Recent Events

  • 31 May 2018 Sangamo Therapeutics intends to file an IND application with the FDA for Fabry's disease by mid 2018
  • 15 May 2017 Preclinical trials in Fabry's disease in USA (IV,Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top